consecutively recruited in Birmingham, U.K., and Coventry, U.K., as part of the U.K. Asian Diabetes Study. A total of 206 normoglycemic control subjects (age 49 years ) were recruited in Birmingham. All subjects were of Punjabi ancestry. Type 2 diabetes was defined according to World Health Organization criteria (5) . The study was approved by the local ethics committee, and written informed consent was obtained from all participants. Venous blood samples were collected from each subject, plasma was removed for autoantibody analysis, and DNA was extracted from the remaining blood using an adaptation of the Nucleon protocol (Nucleon Biosciences, Coatbridge, U.K.). LADA was defined as described above (1).
Antibody analysis
Plasma samples were incubated with an excess of calcium ions overnight, followed by centrifugation. The supernatants were analyzed for autoantibodies to GAD65 and IA-2 using commercially available enzyme-linked immunosorbent assay kits according to the manufacturer's instructions (RSR, Cardiff, U.K.). The reference value was 10 units/ml for GAD65 antibodies and 15 units/ml for IA-2 autoantibodies (based on the World Health Organization standard).
Genetic analysis DNA samples were typed for alleles of HLA-DRB1, -DQA1, and -DQB1 using the phototyping method (6, 7) . The insulin gene variable number tandem repeat (INS-VNTR) type was determined using restriction fragment-length polymorphism analysis with HphI (8) . Alleles of the GCT microsatellite in the major histocompatibility complex class I chainrelated gene-A (MIC-A) gene were typed using the method described by Gambelunghe et al. (9) .
Statistical analysis
Associations between genotype and autoantibody status were analyzed using the 2 test or Fisher's exact test. Differences in continuous variables were investigated using the Mann-Whitney U test. All statistical analyses were performed using SPSS (version 13.0; SPSS, Chicago, IL).
RESULTS -Autoantibodies were detected in 13 of 500 (2.6%) individuals with type 2 diabetes (of whom 8 were GAD65 positive [1.6%] and 6 were IA-2 positive [1.2%], including 1 subject who was positive for both) and 8 of 206 (3.9%) control subjects (of whom 3 were GAD65 positive [1.5%] and 5 were IA-2 positive [2.4%]). There was no significant difference in antibody titers between diabetic and control subjects.
The small number of autoantibodypositive subjects found in this cohort limited investigation of associations between genotype and antibody status in the South Asian population, but some trends were observed. The DRB1*04 and DQB1*0302 alleles were increased in frequency among the IA-2 autoantibody-positive diabetic (P ϭ 0.020 and P ϭ 0.015, respectively) and control (P ϭ not significant) subjects compared with those in subjects lacking these markers. The distribution of the INS-VNTR genotypes did not differ significantly between the autoantibody-positive and autoantibody-negative subjects in either the diabetic or control groups. The MIC-A6 allele was significantly less frequent among IA-2 autoantibody-positive diabetic than autoantibody-negative diabetic subjects (P ϭ 0.044).
Clinical, biochemical, and anthropometric measurements were compared between the autoantibody-positive and autoantibody-negative diabetic subjects (Table 1) . Mean weight and BMI were significantly lower in the autoantibodypositive subjects (P ϭ 0.029 and P ϭ 0.032, respectively). A longer mean duration of diabetes was observed among individuals positive for GAD65 autoantibodies compared with that in autoantibody-negative and IA-2 autoantibodypositive subjects (P ϭ 0.019 and P ϭ 0.009, respectively). A higher percentage of the autoantibody-positive than autoantibody-negative diabetic subjects was treated with insulin (53.8 and 18.8%, respectively) (Table 1) .
CONCLUSIONS -Our study shows that islet autoimmunity is considerably less common among type 2 diabetic individuals of Punjabi ancestry in Birmingham, U.K., than in those of white Caucasian origin. The differences observed between the two ethnic groups may reflect both the higher prevalence of classical type 2 diabetes in South Asians and their lower susceptibility to autoimmune disease. The overall prevalence of islet autoantibodies among the individuals diagnosed with type 2 diabetes in our study cohort (2.6%) was significantly lower than that observed in the pilot study (27%), as was the frequency in the control group (3.9 compared with 9%, respectively) (2). The reasons for these differences are unclear, as both methods were approved by the Diabetes Antibody Standardization Programme (10) . The most likely explanation is that the high prevalence of autoimmunity observed in the pilot study is a spurious result due to the small number of individuals investigated (33 type 2 diabetic and 98 control subjects). A higher percentage of patients positive for diabetes autoantibodies has previously been reported in South Indian (GAD65 and ICA512) (11) and Eastern Indian (GAD65 and IA-2) (12) populations resident in India compared with that in the present study. It remains to be determined whether these differences are due to genetic, environmental, or population-selection influences.
The low frequency of islet autoantibodies in the current study made it difficult to detect statistically significant associations with the genetic loci studied and the clinical, biochemical, and anthropometric measurements. The trends that were observed, however, are generally consistent with previous associations with islet autoimmunity seen in other ethnic groups. Based on the findings of our study, screening for LADA in the U.K. Punjabi population would offer little clinical benefit and is not routinely indicated. Cholesterol Data are means (range) or percentages unless otherwise indicated. *P ϭ 0.019, GAD65 autoantibody positive vs. GAD65 autoantibody negative; †P ϭ 0.009, GAD65 autoantibody positive vs. IA-2 autoantibody positive; ‡P ϭ 0.029, autoantibody positive vs. autoantibody negative; §P ϭ 0.032, autoantibody positive vs. autoantibody negative; P ϭ 0.046, IA-2 autoantibody positive vs. IA-2 autoantibody negative.
